The newly incorporated entity will operate in the pharmaceuticals industry and has not yet started its business, according to the company.
Granules India said the subsidiary has been incorporated to manufacture, promote, sell and distribute pharmaceuticals and other related products in Brazil.
Upon incorporation, Triton Farmaceutica Do Brasil Ltda became a related party to Granules India. However, the company’s promoter and promoter group do not have any interest in the newly incorporated entity, the filing said.
The incorporation requires prior approval of the Reserve Bank of India under the automatic route, according to the company.
The company did not provide an indicative completion period, consideration details or acquisition cost, stating these particulars were not applicable.
As per an earlier, separate, development on July 22, Priyanka Chigurupati, Executive Director of the Hyderabad-based drugmaker had said that Granules India is prepared to expand manufacturing in the US if required, but moving large-scale generic drug production from India would be difficult if US President Donald Trump’s proposed tariffs on imported generic medicines are implemented.
Commenting on Trump’s proposal Chigurupati had said she expects the final tariff structure to be lower than what has been announced. She added that the company is better placed than peers because it has already established manufacturing operations in the US and has the capacity to expand further if needed.Granules India had reported a 60% year-on-year rise in net profit to ₹180 crore for the June quarter Fy27, compared with ₹112.60 crore in the year-ago period. Revenue grew 22% to ₹1,476 crore from ₹1,210 crore in Q1 FY26.
EBITDA rose 37.4% to ₹339 crore from ₹246.5 crore, while the EBITDA margin expanded by over 300 basis points to 23% from 20.3% in the year-ago period.
Shares of Granules India declined 2.60% to ₹824.50 on October 1, at NSE.
Also Read: Nasdaq leads Wall Street higher after weak US jobs data; Dow gains 200 points